Previous 10 | Next 10 |
Genmab (GMAB) announces that the European Commission ((EC)) has granted Novartis (NVS) marketing authorization for the use of Kesimpta (ofatumumab) in the treatment of relapsing forms of multiple sclerosis ((RMS)) in adults. The approval was based on data from the Phase 3 ASCLEPIOS I and...
Halvorsen's 13F portfolio value increased from $27.68B to $36.37B. The number of positions increased from 86 to 96. Viking Global added UnitedHealth, AbCellera Biologics, Walt Disney, and Palo Alto Networks while dropping Analog Devices, CME Group, Comcast, and Exact Sciences. The...
Genmab is collaborating with Seagen to launch tisotumab vedotin in hard to treat cervical cancer. The market potential is below $1bn, but as the first commercial launch of an R&D behemoth, this is a substantial development. In trials, the ADC has shown a better profile than Ke...
The following slide deck was published by Genmab A/S in conjunction with their 2020 Q4 earnings call. For further details see: Genmab A/S 2020 Q4 - Results - Earnings Call Presentation
Image source: The Motley Fool. Genmab A/S (NASDAQ: GMAB) Q4 2020 Earnings Call Feb 23, 2021 , 12:00 p.m. ET Operator Continue reading For further details see: Genmab A/S (GMAB) Q4 2020 Earnings Call Transcript
Genmab A/S (GMAB) Q4 2020 Earnings Conference Call February 23, 2021, 12:00 ET Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - EVP & CFO Anthony Mancini - EVP & COO Judith Klimovsky - EVP & Chief Development Officer Tahamtan Ahmadi - SVP C...
Genmab A/S (GMAB) today announced it would initiate a share repurchase program of up to 200,000 shares.The buyback will start on Feb. 24 and end no later than June 30 of this year.Genmab says it is conducting the repurchase to mitigate dilution caused by warrant exercises and honor commitment...
Genmab A/S (GMAB): FY GAAP EPS of DKK72.21.Revenue of DKK10.11B (+88.3% Y/Y) beats by DKK230M.Press Release For further details see: Genmab A/S beats on revenue
Genmab ([[GMAB]] -4.8%) announces repurchase of up to 200,000 shares.The purpose of the program is mitigating dilution from warrant exercises and honoring commitments under our restricted stock unit program.Completion expected no later than June 30, 2021.The company is entitled to suspend or ...
Genmab (GMAB) and Seagen (SGEN) announce the submission of a Biologics License Application ((BLA)) to the U.S. FDA seeking accelerated approval for tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or a...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 01:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...